Physician profile
Andrea Scott
NPI 1346406899
$3,254.95
in general payments reported to CMS, 2019-2025
15 companies · $831 in 2025
The $831 reported for 2025 was more than what 76% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $178 · 2021: $162 · 2022: $180 · 2023: $497 · 2024: $876 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,203.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,012.94 | 2019-2025 | Dovato, Rukobia, Cabenuva |
| Gilead Sciences, INC. | $902.28 | 2019-2025 | Biktarvy |
| Insmed, INC. | $389.03 | 2023-2025 | Arikayce, Brinsupri |
| Shionogi INC | $306.30 | 2023-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $136.54 | 2024-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $110.81 | 2019-2023 | Vabomere, Orbactiv, Kimyrsa |
| Merck Sharp & Dohme LLC | $108.28 | 2023-2024 | Zerbaxa, Recarbrio, Dificid |
| Abbvie INC. | $81.25 | 2023-2025 | |
| La Jolla Pharmaceutical Company | $75.36 | 2020-2025 | Xerava, Zevtera |
| Aimmune Therapeutics, INC. | $29.92 | 2025 | Vowst |
| Ferring Pharmaceuticals INC. | $24.05 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $23.52 | 2023 | Vivjoa |
| Cormedix INC. | $21.96 | 2024 | Defencath |
| Janssen Biotech, INC. | $16.40 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $16.31 | 2024 | Vibativ |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.